Alport Syndrome: The Rare Genetic Disorder That Affects Kidneys, Hearing, and Vision
Updated: 2 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: September 2026
TL;DR
Alport syndrome is a rare inherited genetic disorder caused by variations in type IV collagen genes. It allows blood and protein to leak into the urine, progressively damages kidney filters, and can cause hearing loss and vision problems. The kidneys, hearing, and vision are the "clinical triad" — though not everyone develops all three. There is no cure yet, but ACE inhibitors and ARB medications started early can slow kidney decline for years, and kidney transplant restores kidney function without the disease returning. About 15% of cases appear with no family history.
Quick Answer
What is Alport syndrome?
Alport syndrome is a rare genetic disorder caused by variations in the type IV collagen genes (COL4A3, COL4A4, or COL4A5), which form the scaffolding of the kidney's filtering membrane — the glomerular basement membrane (GBM) — as well as structures in the ears and eyes.
The first sign is usually microscopic blood in the urine (microhematuria), often present at birth or within the first few years of life, followed later by protein in the urine (proteinuria) as the filter scars.
There are three genetic types: X-linked (XLAS, roughly 40–50% of cases), autosomal recessive (ARAS, about 15%), and autosomal dominant (ADAS, about 40–50%), each with different severity patterns and inheritance odds — and about 15% of cases occur when neither parent carries the gene variant.
Treatment cannot cure the disease but can delay kidney failure for decades: ACE inhibitors or ARBs are started early, SGLT-2 inhibitors are added if protein in the urine stays high, sodium intake is reduced, and kidney transplant replaces kidney function (though it does not restore hearing or vision).
What Is Alport Syndrome?
Alport syndrome is a genetic disorder that affects how well your kidneys work. It lets blood and protein leak into the urine, and over time it can cause progressive kidney damage that may end in kidney failure. It can also cause hearing loss and vision problems because the same collagen the kidneys rely on is present in the ears and eyes.
Your kidneys remove waste products and extra fluid from the blood and release them as urine. At the heart of each kidney are tiny filtering membranes called the glomerular basement membrane (GBM). The GBM keeps blood cells and protein inside the bloodstream and only lets waste and water pass into urine. Alport syndrome weakens exactly this membrane.
The damage starts with collagen. Type IV collagen is made of three individual chains — alpha 3, alpha 4, and alpha 5 — that twist together like rope. In Alport syndrome, the body either fails to make one of these chains or makes faulty ones. Without the full rope, the kidney filter develops gaps.
Because the eyes and ears also contain type IV collagen, the same gene variations that damage the kidneys can affect vision and hearing. Together, kidney problems, hearing loss, and vision problems make up the condition's clinical triad — but you do not need all three to have Alport syndrome.
Key Fact | Detail |
What it is | Rare genetic disorder of type IV collagen genes (COL4A3, COL4A4, COL4A5) |
What it damages | Kidney filters (GBM), inner ears, and eyes |
Clinical triad | Kidney problems, hearing loss, vision problems |
First sign | Blood in urine you cannot see (microhematuria) |
Progression | Blood in urine → protein in urine → kidney scarring → kidney failure |
Inheritance | Usually from one or both parents; about 15% of cases have no affected parent |
Cure | None yet — treatment slows decline; kidney transplant replaces kidney function |
How Common Is Alport Syndrome?
Alport syndrome is rare, but it is likely more common than the numbers suggest. Experts previously believed fewer than 1 in 2,000 people had it, and fewer than 200,000 people in the United States are thought to have the condition.
The picture is changing. Genetic testing is increasingly accessible, and it is uncovering many milder cases. Some milder cases previously diagnosed as a separate condition called focal segmental glomerulosclerosis (FSGS) may actually be caused by Alport syndrome.
European studies add a striking perspective: as many as 1 in 100 people may carry some variation in the type IV collagen genes. Most carriers never develop full Alport syndrome, but the milder end of the spectrum is almost certainly underdiagnosed.
Prevalence Data | Estimate |
People in the U.S. with Alport syndrome | Fewer than 200,000 |
Historical belief | Fewer than 1 in 2,000 people |
People with some type IV collagen gene variation (European studies) | As many as 1 in 100 |
Cases with no affected parent (de novo) | About 15% |
Trend | Rising diagnoses as genetic testing finds milder cases |
What Are the Symptoms of Alport Syndrome?
The earliest sign is one you cannot see. Microhematuria — blood in the urine that is only detectable on a lab test — is usually present at birth or within the first few years of life. Because it is invisible, it is often discovered only when a routine urine test catches it.
Later, proteinuria develops. Scarring in the filtering membrane allows protein to leak into the urine. Once proteinuria appears, chronic kidney disease follows, and kidney function declines progressively — from mild impairment toward worse over time.
Hearing loss behaves differently. It may start at any time and can begin so mildly that it goes unnoticed. A common early clue is trouble hearing in crowded places. The loss is not always gradual — loud noises can make it worse.
Eye problems span a range of severity. Fleck retinopathy — discolored flecks on the retina — does not affect vision. Macular holes, however, are a real danger to sight. People with Alport syndrome are also more likely to scratch the corneal surface of the eye (corneal abrasion).
Organ System | Symptom | Timing and Notes |
Kidneys | Microhematuria (blood in urine) | Usually the first sign; present at birth or in early years; invisible to the eye |
Kidneys | Proteinuria (protein in urine) | Develops later as the filter scars |
Kidneys | Chronic kidney disease / kidney failure | Progressive after proteinuria appears |
Kidneys | Swelling of hands and ankles, fatigue, nausea, vomiting, muscle cramps | Symptoms of advancing kidney failure |
Hearing | Hearing loss | May start at any time; often mild and unnoticed at first |
Hearing | Difficulty hearing in crowded places | Common early clue |
Hearing | Worsening after loud noise exposure | The loss is not always gradual |
Vision | Fleck retinopathy | Discolored retinal flecks; does not affect vision |
Vision | Macular holes | Can threaten sight |
Vision | Corneal abrasion | More likely than in the general population |
What Causes Alport Syndrome?
The cause is always the same: variations in the type IV collagen genes. These genes build the chains that form the filtering membranes of the kidneys, plus key structures in the ears and eyes.
In most cases, one or both biological parents pass the variant down. However, about 15% of cases occur when neither parent carries the variant gene. These new (de novo) variations arise for the first time in the affected person.
Because the condition is genetic, it cannot be prevented. Family history awareness helps in two ways: it supports early detection, and it informs decisions about passing the condition to children.
A practical rule from the source matters for families. If blood is found in your urine — especially if you are young or the blood appears across several tests — get additional testing. Invisible blood in the urine is the earliest detectable marker of this condition.
Cause Fact | Detail |
Root cause | Variations in type IV collagen genes (COL4A3, COL4A4, COL4A5) |
What collagen does | Chains twist like rope; form the GBM filtration membrane |
Where else it appears | Eyes and ears — explaining hearing and vision symptoms |
Inherited from parents | Most cases; one or both parents carry the variant |
New (de novo) cases | About 15% — neither parent has the variant |
Prevention | Not possible; early detection is the best protection |
What Are the Three Types of Alport Syndrome?
Alport syndrome is classified by how the gene variation is inherited. The three types behave differently in severity, inheritance odds, and who is affected.
X-linked Alport syndrome (XLAS) is the most common type, now estimated at about 40–50% of cases (it was previously thought to account for 60–80% before milder cases were recognized). It involves the COL4A5 gene on the X chromosome, which encodes the alpha 5 chain. Males have only one X chromosome, so they cannot compensate: all males with XLAS have symptoms, and most develop kidney failure. Females have two X chromosomes, so one normal copy usually softens the disease. Most females with XLAS will have blood in their urine, but fewer develop significant kidney problems — about 30% develop kidney failure over their lifetime. Inheritance is directional: males pass their Y chromosome to sons (so they cannot pass XLAS to sons) but pass their X to daughters, meaning all daughters of an affected father will have Alport syndrome. Females with XLAS have a 50% chance of passing it to any child.
Autosomal recessive Alport syndrome (ARAS) accounts for about 15% of cases. Both parents carry an altered gene, and the child must inherit it from both. The parents are typically unaware because they are asymptomatic or only mildly affected. COL4A3 and COL4A4 on chromosome 2 encode the alpha 3 and alpha 4 chains, and ARAS involves mutations on both genes. A carrier has a 50% chance of passing one abnormal gene (which usually causes no Alport syndrome) and a 25% chance, when both parents are carriers, of passing both — giving the child ARAS. Severity and inheritance are the same regardless of sex.
There is also a related condition called digenic Alport syndrome, where the two gene variants sit on different genes rather than the same chromosome, as in ARAS.
Autosomal dominant Alport syndrome (ADAS) accounts for about 40–50% of cases. A variation on only one gene in the pair is enough to cause it. It is not sex-dependent: inheritance patterns and severity are the same for everyone. There is a 50% chance of passing the abnormal gene, and if it is passed, ADAS develops. The path can vary even within the same family — some affected people never have blood in their urine, and kidney failure is less common than in XLAS and ARAS.
Type | Share of Cases | Gene Involved | Inheritance Odds | Typical Severity |
X-linked (XLAS) | About 40–50% (was thought 60–80%) | COL4A5 on the X chromosome (alpha 5 chain) | Males: all sons unaffected, all daughters affected; Females: 50% chance per child | Males: severe, most develop kidney failure; Females: milder, about 30% develop kidney failure in lifetime |
Autosomal recessive (ARAS) | About 15% | COL4A3/COL4A4 on chromosome 2 | 25% chance if both parents are carriers | Kidney failure and hearing loss often before age 30; same severity in all sexes |
Autosomal dominant (ADAS) | About 40–50% | Chromosome 2 gene; one altered copy suffices | 50% chance per child | Usually milder; kidney failure less common; average lifespan typical |
Digenic (related) | Variant of recessive pattern | Two variants on different genes | Carrier-dependent | Similar to ARAS |
How Is Alport Syndrome Diagnosed?
Diagnosis begins with the basics. Your provider reviews your health history, examines your symptoms, and takes a biological family history. Then testing confirms what the history suggests.
Urine tests (urinalysis) detect the invisible blood and protein that mark the disease. An estimated glomerular filtration rate (eGFR) measures how well the kidneys are filtering. A kidney biopsy examines the filter membrane directly under a microscope. Genetic testing confirms the diagnosis and — importantly — determines which type of Alport syndrome you have. A hearing test and an eye exam complete the picture, since the ears and eyes are part of the clinical triad.
Genetic testing deserves emphasis. It is the tool that separates the three types, and the type determines treatment urgency, family inheritance odds, and long-term outlook.
Diagnostic Step | What It Shows |
Health history and symptom exam | Baseline assessment |
Biological family history | Inheritance pattern across generations |
Urinalysis (urine tests) | Invisible blood and protein in urine |
eGFR (estimated glomerular filtration rate) | Current kidney filtering function |
Kidney biopsy | Direct microscopic view of the damaged filter membrane |
Genetic testing | Confirms diagnosis and identifies the type (XLAS, ARAS, or ADAS) |
Hearing test | Detects hearing loss, even mild |
Eye exam | Detects fleck retinopathy, macular holes, corneal risk |
What Treatments Are Available for Alport Syndrome?
There is currently no cure for Alport syndrome. Gene therapies are in research but have not succeeded yet, and approval would take years. Clinical research trials do exist for people who want to explore them. The treatment goal today is clear: slow kidney decline and delay kidney failure for as long as possible.
The cornerstone is medication started early. ACE inhibitors or ARBs lower blood pressure, decrease protein in the urine, and protect the kidneys. Timing matters. Males with XLAS, and anyone with ARAS or digenic Alport syndrome, should start an ACE inhibitor or ARB after diagnosis. Females with XLAS or ADAS start when proteinuria appears — or at diagnosis if protein is already present.
When proteinuria stays high despite ACE inhibitors or ARBs, SGLT-2 inhibitors are added. These medications decrease the risk of kidney failure in chronic kidney disease.
Lifestyle supports the medications. Reducing sodium (salt) intake lowers blood pressure and keeps the kidneys and heart healthy.
Kidney transplant deserves a nuanced answer — "yes and no." The new kidney contains normal type IV collagen and normal GBMs, so Alport syndrome will not come back in the transplanted kidney. But the transplant does nothing for the hearing or vision problems, which persist.
Treatment | What It Does | When It Is Used |
ACE inhibitors or ARBs | Lower blood pressure, decrease protein in urine, protect kidneys | Males with XLAS and anyone with ARAS/digenic: at diagnosis; Females with XLAS or ADAS: when proteinuria appears or at diagnosis |
SGLT-2 inhibitors | Decrease kidney failure risk in chronic kidney disease | When high proteinuria persists after ACEi/ARB |
Reduced sodium (salt) intake | Lowers blood pressure; supports kidney and heart health | Ongoing lifestyle measure |
Kidney transplant | Replaces kidney function; Alport does not return in the new kidney | End-stage kidney failure; does not restore hearing or vision |
Gene therapy | Potential future cure | In research; not yet successful or approved |
Research trials | Access to experimental approaches | Available for eligible patients |
What Is the Outlook for Alport Syndrome?
Prognosis depends heavily on the type. The two more severe patterns share a timeline: males with XLAS, and anyone with ARAS, often develop kidney failure and hearing loss before age 30.
Females with XLAS typically have an average lifespan. About 20% develop kidney failure by age 60, and roughly 30% develop it over their lifetime. ADAS is usually the mildest path — most people have an average lifespan, hearing loss and kidney failure are less common, and there is not yet enough research to predict who will develop kidney failure.
One sobering reality shapes the whole prognosis. Chronic kidney disease and kidney failure shorten lifespan. Without dialysis or transplant, kidney failure is fatal. Even with treatment, people with Alport syndrome face an increased risk of dying from heart disease, stroke, and infections. Kidney transplant may bring life expectancy closer to the average.
Prognosis Factor | Outcome |
Males with XLAS / anyone with ARAS | Kidney failure and hearing loss often before age 30 |
Females with XLAS | Usually average lifespan; about 20% kidney failure by 60; about 30% over lifetime |
ADAS | Usually average lifespan; kidney failure less common |
Without dialysis or transplant | Kidney failure is fatal |
With treatment | Increased risk of death from heart disease, stroke, infections |
After kidney transplant | Life expectancy may approach the average; disease does not recur in the new kidney |
How Can You Protect Your Kidney Health With Alport Syndrome?
Early detection is the single most effective protection. If blood is found in your urine — especially repeatedly, or in someone young — push for additional testing. A routine urinalysis costs little and catches the earliest marker of this disease.
Family awareness compounds the benefit. If relatives have Alport syndrome, schedule an appointment. You may be offered blood and urine tests that establish a baseline before symptoms appear. Once diagnosed, starting ACE inhibitors or ARBs at the recommended time — not after symptoms worsen — is what buys the most kidney-preserving years.
Protective Step | Why It Matters |
Urinalysis if blood is found in urine (especially when young or repeated) | Catches microhematuria, the first sign |
Screening if family members have Alport syndrome | Baseline blood and urine tests before symptoms |
Start ACEi/ARB at the recommended time | Slows kidney decline from the earliest point |
Reduce sodium intake | Lowers blood pressure, protects kidneys and heart |
Avoid loud noise exposure | Loud noise can worsen hearing loss |
Regular eye exams | Catches macular holes before they threaten sight |
When Should You See a Provider?
Three situations call for an appointment. First, if you find blood in your urine — visible or invisible on a test. Second, if you notice hearing or vision changes. Third, and importantly, if family members have Alport syndrome: schedule an appointment even without symptoms, because you may qualify for baseline blood and urine testing.
Questions to Ask Your Provider
What type of Alport syndrome do I have?
Will I pass it on to my biological children?
Do I have decreased kidney function?
What medications do you recommend?
How often should I schedule appointments to check kidney health?
Can you refer me to a nephrologist?
Can you recommend any Alport syndrome support groups?
Conclusion: Early Detection Buys Decades of Kidney Health
Alport syndrome begins invisibly — as microscopic blood in the urine, often from birth — and progresses through protein leakage toward kidney failure, with hearing and vision potentially in its wake. The disease is genetic and cannot be prevented, but the gap between diagnosis and kidney failure is wide, and it is yours to defend. ACE inhibitors and ARBs started at the right time, SGLT-2 inhibitors when protein persists, low-sodium habits, and vigilant monitoring can slow decline for years. Kidney transplant, when needed, restores kidney function with a new filter that Alport syndrome will not touch again.
Your next step: if you or a family member has unexplained blood in the urine — especially across multiple tests — or if Alport syndrome runs in your family, schedule an appointment with a healthcare provider this week. Ask specifically for a urinalysis, eGFR testing, and a referral for genetic testing and a nephrologist. Knowing your type changes everything: it sets your medication timeline, your family's inheritance odds, and your long-term plan.
Frequently Asked Questions
Is Alport syndrome hereditary?
Yes. In most cases, one or both biological parents pass down the gene variation that causes Alport syndrome. About 15% of cases occur when neither parent carries the variant — the change arises for the first time in the affected person.
What are the first signs of Alport syndrome?
The first sign is usually microscopic blood in the urine (microhematuria), which is invisible to the eye and typically present at birth or within the first few years of life. It is usually found only through a urine test. Protein in the urine develops later, and kidney disease progresses after that.
Does Alport syndrome cause hearing loss?
Yes, hearing loss is part of the classic clinical triad (kidneys, hearing, vision). It can start at any time, often begins mildly enough to go unnoticed, and is commonly noticed first as difficulty hearing in crowded places. Loud noises can make it worse, and the loss is not always gradual.
Can Alport syndrome be cured?
No cure exists yet. Gene therapies are being researched but have not succeeded, and approval would take years. Treatment focuses on slowing kidney decline with ACE inhibitors or ARBs, adding SGLT-2 inhibitors if proteinuria persists, reducing salt intake, and ultimately kidney transplant — which replaces kidney function and will not develop Alport syndrome.
What is the life expectancy of someone with Alport syndrome?
Prognosis depends on the type. Males with X-linked Alport syndrome and anyone with the recessive type often develop kidney failure and hearing loss before age 30. Females with X-linked disease and people with the dominant type usually have an average lifespan. With kidney transplant, life expectancy may approach the average.
Can a kidney transplant cure Alport syndrome?
A transplant replaces kidney function, and because the new kidney has normal type IV collagen, Alport syndrome will not come back in it. However, the transplant does not help the hearing or vision problems, which continue after surgery.
Can females have Alport syndrome?
Yes. Females with X-linked Alport syndrome usually have a milder course because they have a second, normal copy of the gene. Most will have blood in their urine, but only about 30% develop kidney failure in their lifetime, and about 20% by age 60. The recessive and dominant types affect all sexes equally.
Should my children be tested if I have Alport syndrome?
If you have Alport syndrome, your children should be evaluated, because inheritance odds range from 25% to 100% depending on your type and sex. Ask your provider about genetic testing and baseline urine tests for your children — early detection allows early treatment that preserves kidney function.
References
This article is based on medically reviewed clinical information from the Alport Syndrome Foundation, the National Kidney Foundation's overview of Alport Syndrome, MedlinePlus's Alport Syndrome genetics entry, StatPearls' Alport Syndrome entry (Watson S, Padala SA, Hashmi MF), Savige J, et al., "Alport Syndrome in Women and Girls," Clinical Journal of the American Society of Nephrology (2016), and a European population study on type IV collagen gene variation.
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for medical decisions.
Comments